SI22888B - Polimorfi donepezil hidroklorida in postopek izdelave - Google Patents

Polimorfi donepezil hidroklorida in postopek izdelave Download PDF

Info

Publication number
SI22888B
SI22888B SI9720102A SI9720102A SI22888B SI 22888 B SI22888 B SI 22888B SI 9720102 A SI9720102 A SI 9720102A SI 9720102 A SI9720102 A SI 9720102A SI 22888 B SI22888 B SI 22888B
Authority
SI
Slovenia
Prior art keywords
polymorph
donepezil hydrochloride
donepezil
manufacture
hydrochloride
Prior art date
Application number
SI9720102A
Other languages
English (en)
Other versions
SI22888A (sl
Inventor
Akio Imai
Hideaki Watanabe
Takashi Kajima
Yasushi Ishihama
Akiyo Ohtsuka
Tomohide Tanaka
Jukio Narabu
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=15404413&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI22888(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Priority claimed from PCT/JP1997/001932 external-priority patent/WO1997046527A1/en
Publication of SI22888A publication Critical patent/SI22888A/sl
Publication of SI22888B publication Critical patent/SI22888B/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)

Abstract

Donepezil hidroklorid namreč benzil dimetoksi indanon il metilpiperidin hidroklorid je na voljo v obliki polimorfov ki so pri farmacevtski uporabi odporni proti toploti in vlagi Možno jih je industrijsko proizvajati Opredeljeniso z vrhovi vzorcev pri X žarkovni praškasi difrakciji ter z absorpcijskimi vrhovi pri infrardečem absorpcijskem spektru v kalijevem bromidu

Claims (14)

  1. Eisai Co., Ltd. Polimorfi donepezil hidroklorida in postopek izdelave PATENTNI ZAHTEVKI 1. Donepezil hidroklorid, namreč l-benzil-4-[(5,6-dimetoksi-l-indanon)-2-il]metilpiperidin hidroklorid, v obliki polimorfa (IV), pri čemer je polimorf opredeljen z vrhovi ob spodaj navedenih difrakcijskih stopnjah in spodaj navedeni intenziteti vzorcev praškaste X-žarkovne difrakcije, izraženi z I/I0, kot tudi spodaj navedenih absorpcijskih vrhov pri infrardečih absorpcijskih spektrih v kalijevem bromidu, izraženih v recipročnih centrimetrih, pri čemer velja polimorfi (IV) vrhovi pri praškastih X-žarkovnih difrakcijskih vzorcih so Difrakciiski koti (2Θ.°)_Intenziteta (I/L) 6,24 9,66 11,0412,12 12,54 12,76 13,98 14,42 14,88 15 12 22 24 67 61 27 15 11 2 16,34 12 17,46 100 18,12 25 18,60 32 19,06 15 19,98 74 20,24 41 20,62 34 21,30 48 21,80 63 22,58 78 23,04 46 24,00 32 24,54 49 25,14 90 25,36 99 26,06 34 28,10 41 28,58 39 29,30 31 29.44 28. Valovna števila (cm1) infrardečih absorpcijskih spektrov v kalijevem bromidu so: 401, 431, 459, 467, 490, 506, 518, 561, 586, 606, 631, 651, 709, 758, 766, 857, 944, 1009, 1041, 1106, 1119, 1132, 1213, 1225, 1265, 1304, 1318, 1429, 1458, 1470, 1500, 1589, 1605, 1630, 1647, 1683, 2562, 2577, 2608, 2634, 2689, 2717, 2836, 2924, 2949, 2989, 3007, 3032, 3061, 3322, 3376, 3422 cm '. 3
  2. 2. Postopek izdelave polimorfa (IV) donepezil hidroklorida po zahtevku 1, obsegajoč korak navlaženja v nadaljevanju definiranega polimorfa (II): (2) Polimorfi (II) Vrhovi v vzorcu praškaste X-žarkovne di frakcij e so: Intenziteta (I/Ll 8 100 13 40 38 38 35 17 20 17 19 19 47 24 19 33 22 25 27 18 14 Difrakciiski koti (2Θ.°) 7.40 9,88 12,36 15,54 16,10 16,22 16,48 17,30 18,04 18,44 18.84 19,34 19.84 21,16 22.40 23,18 24,02 24,92 25,72 26.40 27.22_ 4 Valovna števila (cm1) infrardečih absorpcijskih spektrov v kalijevem bromidu so: 699, 748, 762, 845, 947, 1009, 1035, 1067, 1103, 1118, 1129, 1174, 1193, 1206, 1222, 1247, 1267, 1317, 1365, 1422, 1436, 1456, 1465, 1502, 1592, 1607, 1688, 2412, 2489, 2627, 2846, 2868, 2913, 2928, 3435 cm1.
  3. 3. Postopek izdelave polimorfa (IV) donepezil hidroklorida po zahtevku 1, obsegajoč korak raztapljanja donepezila v vodi z dodajanjem tetrahidrofurana ali brez dodajanja le-tega ter z dodajanjem klorovodikove kisline ali vodikovega klorida raztopini.
  4. 4. Postopek izdelave polimorfa (IV) donepezil hidroklorida po zahtevku 1, obsegajoč korak raztapljanja donepezila v klorovodikovi kislini ter dodajanja tetrahidrofurana raztopini.
  5. 5. Postopek izdelave polimorfa (IV) donepezil hidroklorida po zahtevku 1, obsegajoč korak korak raztapljanja donepezila v toluenu ter dodajanja klorovodikove kisline raztopini.
  6. 6. Postopek izdelave polimorfa (IV) donepezil hidroklorida po zahtevku 1, obsegajoč korak raztapljanja donepezila v n-heksanu ter dodajanja klorovodikove kisline raztopini.
  7. 7. Postopek izdelave polimorfa (IV) donepezil hidroklorida po zahtevku 1, obsegajoč korak kristalizacije donepezila v mešanici metanola in klorovodikove kisline. 5
  8. 8. Postopek izdelave polimorfa (IV) donepezil hidroklorida po zahtevku 1, obsegajoč korak korak kristalizacije donepezila iz vode.
  9. 9. Postopek izdelave polimorfa (IV) donepezil hidroklorida po zahtevku 1, obsegajoč korak navlaženja amorfne oblike donepezil hidroklorida.
  10. 10. Postopek izdelave polimorfa (IV) donepezil hidroklorida po zahtevku 1, obsegajoč korak navlaženja polimorfa (II) donepezil hidroklorida
  11. 11. Uporaba farmakološko učinkovite količine donepezil hidroklorida v obliki polimorfa po zahtevku 1 za pripravo zdravila za zdravljenje bolezni, povezanih z acetilholinasterazno aktivnostjo.
  12. 12. Uporaba po zahtevku 11, pri čemer bolezen predstavlja senilna demenca.
  13. 13. Uporaba po zahtevku 11, pri čemer bolezen predstavlja senilna demenca Alzheimerjeve vrste.
  14. 14. Terapevtski sestavek, obsegajoč farmakološko učinkovito količino donepezil hidroklorida v obliki polimorfa po zahtevku 1 in farmakološko sprejemljiv nosilec.
SI9720102A 1996-06-07 1997-06-06 Polimorfi donepezil hidroklorida in postopek izdelave SI22888B (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP14629396 1996-06-07
PCT/JP1996/003881 WO1997046526A1 (en) 1996-06-07 1996-12-27 Stable polymorphs of donepezil (1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine) hydrochloride and process for production
US08/774,802 US6140321A (en) 1996-06-07 1996-12-30 Polymorphs of donepezil hydrochloride and process for production
PCT/JP1997/001932 WO1997046527A1 (en) 1996-06-07 1997-06-06 Polymorphs of donepezil hydrochloride and process for production

Publications (2)

Publication Number Publication Date
SI22888A SI22888A (sl) 2010-04-30
SI22888B true SI22888B (sl) 2010-06-30

Family

ID=15404413

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9720102A SI22888B (sl) 1996-06-07 1997-06-06 Polimorfi donepezil hidroklorida in postopek izdelave

Country Status (17)

Country Link
US (1) US6140321A (sl)
JP (2) JP2005015486A (sl)
KR (1) KR100545851B1 (sl)
CN (1) CN1312129C (sl)
AT (1) ATE445603T1 (sl)
AU (1) AU1153097A (sl)
CA (1) CA2516108C (sl)
DE (1) DE69739622D1 (sl)
DK (1) DK1211243T3 (sl)
ES (1) ES2330997T3 (sl)
HK (1) HK1080078A1 (sl)
HU (1) HUP0900417A3 (sl)
PT (1) PT1211243E (sl)
SI (1) SI22888B (sl)
UA (1) UA60307C2 (sl)
WO (1) WO1997046526A1 (sl)
ZA (1) ZA975064B (sl)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69805305T2 (de) * 1997-08-21 2002-12-05 P.N. Gerolymatos S.A., Kruoneri Verwendung von phanquinon zur behandlung von alzheimer's krankheit
AU9454098A (en) * 1997-09-24 1999-04-12 Nova Molecular, Inc. Methods for increasing apoe levels for the treatment of neurodegenerative disease
PT1140090E (pt) 1999-01-07 2005-05-31 Gerolymatos P N Sa Utilizacao de fanquinona para o tratamento ou prevencao da perda de memoria
ATE277011T1 (de) * 1999-03-03 2004-10-15 Eisai Co Ltd Flouride von 4-substituierten piperidin-derivaten
WO2001066114A1 (en) 2000-03-03 2001-09-13 Eisai Co., Ltd. Novel methods using cholinesterase inhibitors
US20060183776A9 (en) * 2000-03-03 2006-08-17 Eisai Co., Ltd. Liquid dosage formulations of donepezil
DE60129828T2 (de) * 2000-09-25 2008-04-30 Eisai R&D Management Co., Ltd. Verfahren zur herstellung eines multiform-kristalls von donepezil hydrochlorid
US20050249786A1 (en) * 2001-09-28 2005-11-10 Solubest Ltd. Hydrophilic dispersions of nanoparticles of inclusion complexes of amorphous compounds
US20050233003A1 (en) * 2001-09-28 2005-10-20 Solubest Ltd. Hydrophilic dispersions of nanoparticles of inclusion complexes of salicylic acid
US20050191359A1 (en) * 2001-09-28 2005-09-01 Solubest Ltd. Water soluble nanoparticles and method for their production
US20050227911A1 (en) * 2001-09-28 2005-10-13 Solubest Ltd. Hydrophilic dispersions of nanoparticles of inclusion complexes of macromolecules
US6878693B2 (en) * 2001-09-28 2005-04-12 Solubest Ltd. Hydrophilic complexes of lipophilic materials and an apparatus and method for their production
US7700851B2 (en) * 2001-11-13 2010-04-20 U.S. Smokeless Tobacco Company Tobacco nicotine demethylase genomic clone and uses thereof
US20050142088A1 (en) * 2002-02-07 2005-06-30 Mitsuru Mizuno Hair growth stimulants, percutaneous preparations and method of stimulating hair growth
JP4336979B2 (ja) * 2002-05-01 2009-09-30 三栄源エフ・エフ・アイ株式会社 アラビアガムの改質方法
IL150509A (en) 2002-07-01 2007-07-04 Joseph Kaspi Pharmaceutical preparations containing donafazil hydrochloride
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20060014801A1 (en) * 2002-11-22 2006-01-19 The Johns Hopkins University Prevention and treatment of cognitive impairment using (R)-(-)-5-methyl-1-nicotynoyl-2-pyrazoline (MNP) and analogs
IL154370A0 (en) * 2003-02-10 2003-09-17 Chemagis Ltd Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same
US20050288330A1 (en) * 2004-06-29 2005-12-29 Avinash Naidu Process for producing a polymorphic form of (1-Benzyl-4-[(5,6-dimethoxy-1-indanone)-2-yl] methyl piperidine hydrochloride (donepezil hydrochloride)
US7521481B2 (en) * 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
WO2004092137A1 (en) * 2003-04-16 2004-10-28 Hetero Drugs Limited Novel crystalline forms of donepezil hydrochloride
WO2004099142A1 (en) * 2003-05-05 2004-11-18 Ranbaxy Laboratories Limited Hydrobromide salt of benzyl-piperidylmethyl-indanone and its polymorphs
UA83504C2 (en) 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
EP1776089A2 (en) * 2003-12-31 2007-04-25 Actavis Group hf Donepezil formulations
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
TW200533371A (en) * 2004-04-15 2005-10-16 Dainippon Pharmaceutical Co Medicament comprising a combination of an acetylcholinesterase inhibitor and a 5-substituted-3-oxadiazolyl-1,6-naphthyridin-2(1h)-one derivative
WO2005112946A1 (en) * 2004-05-14 2005-12-01 The Johns Hopkins University Method for improving cognitive function by co-administration of a gabab receptor antagonist and an acetylcholinesterase inhibitor
WO2006015338A2 (en) * 2004-07-30 2006-02-09 Dr. Reddy's Laboratories Ltd. Crystalline form of donepezil hydrochloride
US7371906B2 (en) * 2004-08-24 2008-05-13 Eastman Kodak Company Process for photo-oxidative stability improvements
AU2005288521A1 (en) * 2004-09-29 2006-04-06 Chemagis Ltd. Use of purified donepezil maleate for preparing pharmaceutically pure amorphous donepezil hydrochloride
NZ553804A (en) * 2004-09-29 2010-07-30 Bayer Schering Pharma Ag Thermodynamically stable form of bay 43-9006 tosylate
CA2584547C (en) * 2004-10-19 2014-07-08 Miha Vrbinc Solid pharmaceutical composition comprising donepezil hydrochloride
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
CA2590533C (en) * 2004-11-23 2010-09-07 Warner-Lambert Company Llc 7-(2h-pyrazol-3-yl)-3,5-dihydroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for the treatment of lipidemia
US20060122226A1 (en) 2004-12-08 2006-06-08 Itai Adin Crystalline forms of Donepezil base
CN101087618A (zh) * 2004-12-23 2007-12-12 航行药物公司 醋酸亮丙瑞林和乙酰胆碱酯酶抑制剂或nmda受体抑制剂在阿尔茨海默氏病治疗中的应用
US20060270709A1 (en) * 2005-04-04 2006-11-30 Eisai Co. Ltd. Dihydropyridine compounds and compositions for headaches
US20070026075A1 (en) * 2005-07-28 2007-02-01 Jutaro Shudo Gelled donepezil compositions and methods for making and using the same
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US7274339B2 (en) * 2005-09-16 2007-09-25 Smartant Telecom Co., Ltd. Dual-band multi-mode array antenna
DE102005060377A1 (de) 2005-12-16 2007-06-21 Ratiopharm Gmbh Pharmazeutische Zusammensetzung enthaltend Donepezilhydrochlorid, Tablette hieraus und Verfahren zu deren Herstellung
HU227474B1 (en) * 2005-12-20 2011-07-28 Richter Gedeon Nyrt Process for industrial scale production of high purity donepezil hydrochloride polymorph i.
WO2007108011A2 (en) * 2006-03-20 2007-09-27 Ind-Swift Laboratories Limited Process for the preparation of highly pure donepezil
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
CN102838599A (zh) 2006-05-04 2012-12-26 贝林格尔.英格海姆国际有限公司 多晶型
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
JP5097359B2 (ja) * 2006-05-09 2012-12-12 久光製薬株式会社 ドネペジル経皮吸収型製剤
AR062927A1 (es) * 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
AR063319A1 (es) * 2006-10-16 2009-01-21 Medichem Sa Proceso mejorado para preparar la forma polimorfica i de clorhidrato de donepezilo (2,3-dihidro-5,6-dimetoxi-2-[[1-(fenilmetil)-4-piperidin]metil-1h-inden-1-ona)
MX2009004516A (es) 2006-10-27 2009-08-12 Medivation Neurology Inc Metodos y terapias de combinacion para tratar enfermedad de alzheimer.
EP2081902A1 (en) * 2006-11-09 2009-07-29 Bayer Schering Pharma Aktiengesellschaft Polymorph iii of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide
WO2008058644A1 (en) * 2006-11-14 2008-05-22 Bayer Schering Pharma Aktiengesellschaft Polymorph ii of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide
US20100099714A1 (en) * 2007-03-05 2010-04-22 Eisai R&D Management Co., Ltd. AMPA and NMDA Receptor Antagonists for Neurodegenerative Diseases
JP2010524844A (ja) * 2007-04-26 2010-07-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 認知症のためのシンナミド化合物
WO2009084030A2 (en) * 2007-12-03 2009-07-09 Neuland Laboratories Ltd. Improved process for the preparation of (1-benzyl-4-(5,6,- dimethoxyind anone-2-yl)methylpiperidine) hydrochloride-form iii
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
AU2009290911A1 (en) 2008-09-10 2010-03-18 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
JP5488956B2 (ja) * 2008-11-25 2014-05-14 株式会社Dnpファインケミカル宇都宮 (±)2−(ジメチルアミノ)−1−{〔O−(m−メトキシフェネチル)フェノキシ〕メチル}エチル水素サクシナート塩酸塩のI形結晶とII形結晶の混晶の製造法
AU2009331471B2 (en) 2008-12-23 2015-09-03 Boehringer Ingelheim International Gmbh Salt forms of organic compound
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
WO2011061591A1 (en) 2009-11-18 2011-05-26 Jubilant Life Sciences Limited Improved process for the preparation of 1-benzyl-4-(5,6-dimethoxy-1-indanone)-2-yl)methyl piperidine hydrochloride form-iii
KR102668834B1 (ko) 2009-11-27 2024-05-24 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 dpp-iv 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
IT1397912B1 (it) * 2010-01-28 2013-02-04 Chemi Spa Nuovo polimorfo dell'estere 6-dietilamminometil-2-naftilico dell'acido 4-idrossicarbamoil-fenil-carbammico cloridrato.
WO2011100373A1 (en) 2010-02-09 2011-08-18 The Johns Hopkins University Methods and compositions for improving cognitive function
EP2366378A1 (en) 2010-03-01 2011-09-21 Dexcel Pharma Technologies Ltd. Sustained-release donepezil formulations
US20110251239A1 (en) 2010-04-07 2011-10-13 Eisai Inc. Combination therapy for the treatment of dementia
MX2012011604A (es) * 2010-04-07 2013-02-27 Onyx Therapeutics Inc Inhibidor de inmunoproteasoma de péptido epoxicetona cristalino.
ES2935300T3 (es) 2010-05-05 2023-03-03 Boehringer Ingelheim Int Combiterapia
WO2011151359A1 (en) 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
KR20230051307A (ko) 2010-06-24 2023-04-17 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
US20130267560A1 (en) 2010-10-22 2013-10-10 Cadila Healthcare Limited Sustained release pharmaceutical compositions of donepezil
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
EA030121B1 (ru) 2011-07-15 2018-06-29 Бёрингер Ингельхайм Интернациональ Гмбх Замещенные хиназолины, их получение и их применение в фармацевтических композициях
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
CN103012247B (zh) * 2013-01-18 2014-12-10 浙江东亚药业有限公司 一种盐酸多奈哌齐无水i晶型的制备方法
CN103965188A (zh) * 2013-01-29 2014-08-06 中山大学 含硒多奈哌齐类似物
EP3827820A1 (en) 2013-03-15 2021-06-02 The Johns Hopkins University Brivaracetam for improving cognitive function
JP6433482B2 (ja) 2013-03-15 2018-12-05 エージンバイオ, インコーポレイテッド 認知機能を改善するための方法および組成物
CA2921308A1 (en) 2013-08-16 2015-02-19 Universiteit Maastricht Treatment of cognitive impairment with pde4 inhibitor
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
WO2016191288A1 (en) 2015-05-22 2016-12-01 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
EP4233840A3 (en) 2016-06-10 2023-10-18 Boehringer Ingelheim International GmbH Combinations of linagliptin and metformin
CN106397306B (zh) * 2016-10-20 2019-03-08 山东罗欣药业集团股份有限公司 一种盐酸多奈哌齐晶型化合物及其制备方法
US10369187B2 (en) 2017-02-09 2019-08-06 Vanderbilt University Peptide regulators of JNK family kinases
WO2020240505A1 (en) 2019-05-31 2020-12-03 TECNIMEDE - Sociedade Técnico-medicinal, SA Immediate release fixed-dose combination of memantine and donepezil
WO2024145323A1 (en) 2022-12-28 2024-07-04 Corium, Llc Pre-mixing method of preparing transdermal delivery system
WO2024145319A1 (en) 2022-12-28 2024-07-04 Corium, Llc Method of preparing transdermal delivery system

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI95572C (fi) * 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi

Also Published As

Publication number Publication date
HK1080078A1 (en) 2006-04-21
CN1699343A (zh) 2005-11-23
CN1312129C (zh) 2007-04-25
HU0900417D0 (en) 2009-08-28
JP2009040783A (ja) 2009-02-26
ATE445603T1 (de) 2009-10-15
CA2516108C (en) 2008-12-02
UA60307C2 (uk) 2003-10-15
ZA975064B (en) 1998-04-01
AU1153097A (en) 1998-01-05
HUP0900417A3 (en) 2012-12-28
ES2330997T3 (es) 2009-12-18
KR20040104707A (ko) 2004-12-10
WO1997046526A1 (en) 1997-12-11
CA2516108A1 (en) 1997-12-11
KR100545851B1 (ko) 2006-01-24
DK1211243T3 (da) 2010-02-08
PT1211243E (pt) 2009-11-06
DE69739622D1 (de) 2009-11-26
US6140321A (en) 2000-10-31
SI22888A (sl) 2010-04-30
JP2005015486A (ja) 2005-01-20

Similar Documents

Publication Publication Date Title
SI22888B (sl) Polimorfi donepezil hidroklorida in postopek izdelave
SI9720038B (sl) Polimorfi donepezil hidroklorida in postopek izdelave
AU2004281216B2 (en) Derivatives of n-[phenyl(alkylpiperidine-2-yl)methyl]benzamide, preparation method thereof and application of same in therapeutics
DE3856491T2 (de) Piperidin Derivate als anticholinerge Linkstoffe
US20030158415A1 (en) Novel opiate compounds, methods of making and methods of use
NO312955B1 (no) Sykliske aminderivater, farmasöytisk preparat og anvendelse av derivatene for fremstilling av et medikament
NO314354B1 (no) Enantiomerrene estere, fremgangsmåte for deres fremstilling og deres anvendelse i legemidler
EP2358675B9 (en) 4-[2-(2-Fluorophenoxymethyl)phenyl]piperidine compounds
JP2007503423A (ja) フェキソフェナジンの結晶多形、及びそれらを製造する方法
PT1761492E (pt) Oxalato de 1-benzil-4-[(5,6-dimetoxi-1-indanon)-2-il] metil-piperidina (oxalato de donepezil) e seus polimorfos
AU2009272303B2 (en) Novel compounds active as muscarinic receptor antagonists
JPS6341901B2 (sl)
JPH09508893A (ja) シグマ受容体のリガンドである 新規2−アリールアルケニルアザシクロアルカン誘導体、その製造方法及び治療薬としてのその使用
JPWO2002026709A1 (ja) 塩酸ドネペジルの多形結晶の製造法
EP2550252B1 (en) 1-(2-phenoxymethylheteroaryl)piperidine and piperazine compounds
DE2158077A1 (de) Derivate des l-(3,3-Diphenyl-propyl)piperidins, ihre Herstellung und diese enthaltende Arzneimittel
NO20060377L (no) Polymorfer av donepezilhydroklorid og fremgangsmater for deres fremstilling
US20050288330A1 (en) Process for producing a polymorphic form of (1-Benzyl-4-[(5,6-dimethoxy-1-indanone)-2-yl] methyl piperidine hydrochloride (donepezil hydrochloride)
Feng et al. Syntheses of 3-carbomethoxy-4-(aryl) piperidines and In vitro and In vivo pharmacological evaluation: identification of inhibitors of the human dopamine transporter
JPH04500521A (ja) ムスカリンレセプター拮抗薬
NO319534B1 (no) Mellomprodukt og fremgangsmater for fremstilling av antihistaminiske piperidinderivater og anvendelse derav for fremstilling av et medikament.
Hojahmat et al. Lobeline esters as novel ligands for neuronal nicotinic acetylcholine receptors and neurotransmitter transporters
Clarke et al. In pursuit of analgetic agents. Hydro-1, 3-ethanoindeno [2, 1-c] pyridines and homologs
DE60006698T2 (de) Unsubstituierte ethyl- und propylderivate von phenoxythienoisoxazolen als d4 antagonisten
Maynard et al. A convergent synthesis of 4-(2-benzothiazoyl) piperidines with antihistamic activity

Legal Events

Date Code Title Description
OU02 Decision according to article 73(2) ipa 1992, publication of decision on partial fulfilment of the invention and change of patent claims

Effective date: 20100515

KO00 Lapse of patent

Effective date: 20170301